Sam Klempner, MD
Sam Klempner, MD
About Sam Klempner, MD
Dr. Klempner completed his residency in internal medicine at Brigham and Women’s Hospital/Harvard Medical School, followed by a combined hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School. While at Harvard Dr. Klempner studied the mechanisms of resistance to targeted therapies in tumor cells in the lab of Dr. Lewis Cantley, PhD. Dr. Klempner is board certified in medical oncology, hematology, and internal medicine, and belongs to several oncology research societies including the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), the American Association for Cancer Research (AACR). His work has been published in multiple journals including Journal of Clinical Oncology (JCO), Cancer Discovery, Lancet Oncology, JAMA Oncology, Annals of Oncology and others. He is an active member of the ASCO TAPUR trial molecular tumor board and serves on the editorial board of JCO Precision oncology.
As a member of the gastrointestinal cancer group at MGH Dr. Klempner works in a multidisciplinary team to optimize and individualize treatment using molecular characterization across all stages of GI cancers. He conducts clinical trials and translational research with new targeted agents and immune therapies, and is active in the gastroesophageal cancer community where he serves on the advisory board of Debbie's Dream Foundation and Hope for Stomach Cancer. He has received several awards for his care of patients with GI cancers. Originally from Wayland, MA he is an avid Boston sports fan.
Departments, Centers, & Programs:
Clinical Interests:
- Stomach (gastric) cancer
- Esophageal cancer
- Novel targeted agents and personalized therapy
- Clinical trials, clinical research
- Translational research
- Gastrointestinal cancer
- Targeted therapies
- Clinical trials of new agents
Treats:
- Adult
Languages:
- Spanish
Locations
Mass General Hospital Cancer Center
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-724-4000
Phone: 617-643-4976
Fax: 617-726-0452
Medical Education
- MD, University of Massachusetts Medical School
- Residency, Brigham and Women's Hospital
- Fellowship, Beth Israel Deaconess Medical Center
American Board Certifications
- Medical Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
- Hematology, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- MassHealth
- Medicare
- Medicare - ACD
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Klempner's research is focused on identifying molecular subgroups in gastric and esophageal cancers and translating this information to new treatment approaches for these difficult cancers. He has interests in circulating tumor DNA, cancer biomarkers, and peritoneal disease and ascites in GI cancers.
Publications
-
View my most recent publications at PubMed
Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J. FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist. 2019 Jun 27;. doi: 10.1634/theoncologist.2019-0121.
Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.Oncologist. 2019 Apr;24(4):475-482.
Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clin Cancer Res. 2018 Apr 15;24(8):1881-1890.
Patient Gateway
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
2021 Virtual Survivorship Conference
Join us for this free webinar series. We welcome anyone living with, through, and beyond cancer and their family members and friends.
#1 Research Hospital in America
Mass General is the #1 Research Hospital in America and the only hospital to be recognized in all 16 specialties assessed by U.S. News & World Report.